Research
Hormonal
Tirzepatide reduces the incidence of obesity-related complications, specifically knee replacements (29-46% reduction) and type 2 diabetes (25-48% reduction), compared to liraglutide.
Tirzepatide treatment is associated with significantly lower rates of knee replacements and type 2 diabetes compared to liraglutide, likely due to greater weight loss and prediabetes reversal.
GoodSupportsHIGH confidence
In both populations, all doses of tirzepatide demonstrated reductions in at least five of seven complications compared to liraglutide, most notably for knee replacements (29–46% reduction) and diabetes (25–48% reduction).
Why this rating
Derived from a simulation model using network meta-analysis data.
Source
Cost-Effectiveness of Tirzepatide Versus Liraglutide, Both Adjunct to Diet and Exercise, for Patients with Obesity or Overweight: A UK Perspective
Matthew Capehorn et al. · Advances in Therapy · 2025
DOI 10.1007/s12325-025-03288-3
unknownCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →